Trial · NCT00070070
Results by group56
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 56
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Dose Limiting Toxicities | Cohort 1 | 0 | Participants | ||
| Number of Participants With Dose Limiting Toxicities | Cohort 2 | 0 | Participants | ||
| Number of Participants With Dose Limiting Toxicities | Cohort 3 | 0 | Participants | ||
| Number of Participants With Dose Limiting Toxicities | Cohort 4 | 0 | Participants | ||
| Number of Patients Developing NY-ESO-1 Antibodies After Treatment | Cohort 1 | Number of Participants with NY-ESO-1 Antibodies at Baseline and After Treatment | 1 | Participants | |
| Number of Patients Developing NY-ESO-1 Antibodies After Treatment | Cohort 2 | Number of Participants with NY-ESO-1 Antibodies at Baseline and After Treatment | 0 | Participants | |
| Number of Patients Developing NY-ESO-1 Antibodies After Treatment | Cohort 3 | Number of Participants with NY-ESO-1 Antibodies at Baseline and After Treatment | 0 | Participants | |
| Number of Patients Developing NY-ESO-1 Antibodies After Treatment | Cohort 4 | Number of Participants with NY-ESO-1 Antibodies at Baseline and After Treatment | 0 | Participants | |
| Number of Patients Developing NY-ESO-1 Antibodies After Treatment | Cohort 1 | Number of Participants with No NY-ESO-1 Antibodies at Baseline and Antibodies After Treatment | 0 | Participants | |
| Number of Patients Developing NY-ESO-1 Antibodies After Treatment | Cohort 2 | Number of Participants with No NY-ESO-1 Antibodies at Baseline and Antibodies After Treatment | 0 | Participants | |
| Number of Patients Developing NY-ESO-1 Antibodies After Treatment | Cohort 3 | Number of Participants with No NY-ESO-1 Antibodies at Baseline and Antibodies After Treatment | 0 | Participants | |
| Number of Patients Developing NY-ESO-1 Antibodies After Treatment | Cohort 4 | Number of Participants with No NY-ESO-1 Antibodies at Baseline and Antibodies After Treatment | 4 | Participants | |
| Number of Patients Developing NY-ESO-1 Antibodies After Treatment | Cohort 1 | Number of Participants with No NY-ESO-1 Antibodies at Baseline and No Antibodies After Treatment | 0 | Participants | |
| Number of Patients Developing NY-ESO-1 Antibodies After Treatment | Cohort 2 | Number of Participants with No NY-ESO-1 Antibodies at Baseline and No Antibodies After Treatment | 0 | Participants | |
| Number of Patients Developing NY-ESO-1 Antibodies After Treatment | Cohort 3 | Number of Participants with No NY-ESO-1 Antibodies at Baseline and No Antibodies After Treatment | 0 | Participants | |
| Number of Patients Developing NY-ESO-1 Antibodies After Treatment | Cohort 4 | Number of Participants with No NY-ESO-1 Antibodies at Baseline and No Antibodies After Treatment | 1 | Participants | |
| Number of Patients With CD4+ and CD8+ T-cell Responses. | Cohort 1 | CD4+ T-Cell Responses / Number of Participants with Responses | 1 | Participants | |
| Number of Patients With CD4+ and CD8+ T-cell Responses. | Cohort 2 | CD4+ T-Cell Responses / Number of Participants with Responses | 0 | Participants | |
| Number of Patients With CD4+ and CD8+ T-cell Responses. | Cohort 3 | CD4+ T-Cell Responses / Number of Participants with Responses | 0 | Participants | |
| Number of Patients With CD4+ and CD8+ T-cell Responses. | Cohort 4 | CD4+ T-Cell Responses / Number of Participants with Responses | 5 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00070070/results